201 related articles for article (PubMed ID: 26260925)
1. Enhanced molecular mobility of ordinarily structured regions drives polyglutamine disease.
Lupton CJ; Steer DL; Wintrode PL; Bottomley SP; Hughes VA; Ellisdon AM
J Biol Chem; 2015 Oct; 290(40):24190-200. PubMed ID: 26260925
[TBL] [Abstract][Full Text] [Related]
2. Examination of Ataxin-3 (atx-3) Aggregation by Structural Mass Spectrometry Techniques: A Rationale for Expedited Aggregation upon Polyglutamine (polyQ) Expansion.
Scarff CA; Almeida B; Fraga J; Macedo-Ribeiro S; Radford SE; Ashcroft AE
Mol Cell Proteomics; 2015 May; 14(5):1241-53. PubMed ID: 25700012
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel site of interaction between ataxin-3 and the amyloid aggregation inhibitor polyglutamine binding peptide 1.
Knight PD; Karamanos TK; Radford SE; Ashcroft AE
Eur J Mass Spectrom (Chichester); 2018 Feb; 24(1):129-140. PubMed ID: 29334808
[TBL] [Abstract][Full Text] [Related]
4. The Machado-Joseph disease-associated expanded form of ataxin-3: Overexpression, purification, and preliminary biophysical and structural characterization.
Contessotto MGG; Rosselli-Murai LK; Garcia MCC; Oliveira CLP; Torriani IL; Lopes-Cendes I; Murai MJ
Protein Expr Purif; 2018 Dec; 152():40-45. PubMed ID: 30036587
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
[TBL] [Abstract][Full Text] [Related]
6. Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease.
Carvalho AL; Silva A; Macedo-Ribeiro S
Adv Exp Med Biol; 2018; 1049():275-288. PubMed ID: 29427109
[TBL] [Abstract][Full Text] [Related]
7. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
8. Capturing the Conformational Ensemble of the Mixed Folded Polyglutamine Protein Ataxin-3.
Sicorello A; Różycki B; Konarev PV; Svergun DI; Pastore A
Structure; 2021 Jan; 29(1):70-81.e5. PubMed ID: 33065068
[TBL] [Abstract][Full Text] [Related]
9. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
[TBL] [Abstract][Full Text] [Related]
10. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step.
Ellisdon AM; Thomas B; Bottomley SP
J Biol Chem; 2006 Jun; 281(25):16888-16896. PubMed ID: 16624810
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein.
Ellisdon AM; Pearce MC; Bottomley SP
J Mol Biol; 2007 Apr; 368(2):595-605. PubMed ID: 17362987
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation.
Johnson SL; Ranxhi B; Libohova K; Tsou WL; Todi SV
Elife; 2020 Sep; 9():. PubMed ID: 32955441
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions as a survival strategy against abnormal aggregation.
Masino L; Nicastro G; Calder L; Vendruscolo M; Pastore A
FASEB J; 2011 Jan; 25(1):45-54. PubMed ID: 20810784
[TBL] [Abstract][Full Text] [Related]
14. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
15. Protein Environment: A Crucial Triggering Factor in Josephin Domain Aggregation: The Role of 2,2,2-Trifluoroethanol.
Visentin C; Navarro S; Grasso G; Regonesi ME; Deriu MA; Tortora P; Ventura S
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042316
[TBL] [Abstract][Full Text] [Related]
16. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3.
Gales L; Cortes L; Almeida C; Melo CV; Costa MC; Maciel P; Clarke DT; Damas AM; Macedo-Ribeiro S
J Mol Biol; 2005 Oct; 353(3):642-54. PubMed ID: 16194547
[TBL] [Abstract][Full Text] [Related]
17. Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease.
Chow MK; Paulson HL; Bottomley SP
J Mol Biol; 2004 Jan; 335(1):333-41. PubMed ID: 14659761
[TBL] [Abstract][Full Text] [Related]
18. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamine expansion diseases: More than simple repeats.
Silva A; de Almeida AV; Macedo-Ribeiro S
J Struct Biol; 2018 Feb; 201(2):139-154. PubMed ID: 28928079
[TBL] [Abstract][Full Text] [Related]
20. A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3.
Weber JJ; Golla M; Guaitoli G; Wanichawan P; Hayer SN; Hauser S; Krahl AC; Nagel M; Samer S; Aronica E; Carlson CR; Schöls L; Riess O; Gloeckner CJ; Nguyen HP; Hübener-Schmid J
Brain; 2017 May; 140(5):1280-1299. PubMed ID: 28334907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
